JP7386544B2 - テトラベナジン経皮送達デバイス - Google Patents

テトラベナジン経皮送達デバイス Download PDF

Info

Publication number
JP7386544B2
JP7386544B2 JP2020559388A JP2020559388A JP7386544B2 JP 7386544 B2 JP7386544 B2 JP 7386544B2 JP 2020559388 A JP2020559388 A JP 2020559388A JP 2020559388 A JP2020559388 A JP 2020559388A JP 7386544 B2 JP7386544 B2 JP 7386544B2
Authority
JP
Japan
Prior art keywords
adhesive composition
transdermal delivery
tetrabenazine
adhesive
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522240A5 (https=
JPWO2019209940A5 (https=
JP2021522240A (ja
Inventor
スレシュ ボルサディア
カルパナ パテル
ホック エス． タン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shinkei Therapeutics Inc
Original Assignee
Shinkei Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinkei Therapeutics Inc filed Critical Shinkei Therapeutics Inc
Publication of JP2021522240A publication Critical patent/JP2021522240A/ja
Publication of JP2021522240A5 publication Critical patent/JP2021522240A5/ja
Publication of JPWO2019209940A5 publication Critical patent/JPWO2019209940A5/ja
Application granted granted Critical
Publication of JP7386544B2 publication Critical patent/JP7386544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020559388A 2018-04-25 2019-04-24 テトラベナジン経皮送達デバイス Active JP7386544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662456P 2018-04-25 2018-04-25
US62/662,456 2018-04-25
PCT/US2019/028900 WO2019209940A1 (en) 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device

Publications (4)

Publication Number Publication Date
JP2021522240A JP2021522240A (ja) 2021-08-30
JP2021522240A5 JP2021522240A5 (https=) 2022-04-20
JPWO2019209940A5 JPWO2019209940A5 (https=) 2022-04-20
JP7386544B2 true JP7386544B2 (ja) 2023-11-27

Family

ID=68295781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559388A Active JP7386544B2 (ja) 2018-04-25 2019-04-24 テトラベナジン経皮送達デバイス

Country Status (15)

Country Link
US (2) US12144899B2 (https=)
EP (1) EP3784237B1 (https=)
JP (1) JP7386544B2 (https=)
KR (1) KR102952482B1 (https=)
CN (1) CN112165942B (https=)
AU (1) AU2019261403B2 (https=)
BR (1) BR112020021700A2 (https=)
CA (1) CA3097189A1 (https=)
DK (1) DK3784237T3 (https=)
ES (1) ES2968827T3 (https=)
IL (1) IL278185B2 (https=)
MX (1) MX2020011269A (https=)
TW (1) TWI832854B (https=)
WO (1) WO2019209940A1 (https=)
ZA (1) ZA202006415B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US20220362165A1 (en) * 2019-10-22 2022-11-17 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
IL296624A (en) * 2020-03-30 2022-11-01 Shinkei Therapeutics Inc Transdermal delivery of dextromethorphan
CN116036055A (zh) * 2023-03-16 2023-05-02 上海世领制药有限公司 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517493A (ja) 1997-09-26 2001-10-09 ノーヴェン ファーマシューティカルズ インコーポレイテッド 生体接着剤組成物及び活性薬剤の局所投与方法
US20060078604A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
JP2012503010A (ja) 2008-09-18 2012-02-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 小胞モノアミン輸送体２のベンゾキノリン阻害剤
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
JP2013528631A (ja) 2010-06-17 2013-07-11 エルテーエス ローマン テラピー−ジステーメ アーゲー メマンチンの経皮投与
JP2015515475A (ja) 2012-04-04 2015-05-28 イヴァックス・インターナショナル・ゲーエムベーハー 併用療法のための医薬組成物
JP2016520638A (ja) 2013-06-04 2016-07-14 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システム
WO2017003935A1 (en) 2015-06-27 2017-01-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
JP2017514850A (ja) 2014-05-06 2017-06-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313723A (ja) 1987-06-16 1988-12-21 Nitto Electric Ind Co Ltd 外用貼付剤
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP4988080B2 (ja) * 1997-09-05 2012-08-01 日東電工株式会社 経皮吸収型製剤
WO2002024157A2 (en) * 2000-09-19 2002-03-28 National Starch And Chemical Investment Holding Corporation Acryl adhesive useful in transdermal drug delivery systems
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
EP2872126B1 (en) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
EA201691512A1 (ru) 2014-01-27 2017-01-30 Оспекс Фармасьютикалз, Инк. Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
NZ760790A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
EA036837B1 (ru) 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
CN107028916B (zh) * 2016-02-04 2020-05-12 北京泰德制药股份有限公司 含有布比卡因或其药用盐的皮肤外用制剂
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
US20190111035A1 (en) 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
TWI741168B (zh) * 2017-04-28 2021-10-01 日商日東電工股份有限公司 經皮吸收製劑
WO2019016357A1 (en) 2017-07-20 2019-01-24 Neurolixis USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS
GB2565049B (en) 2017-07-27 2020-06-10 Reckitt Benckiser Health Ltd A head assembly of a dermaplaning device
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US20190374521A1 (en) 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517493A (ja) 1997-09-26 2001-10-09 ノーヴェン ファーマシューティカルズ インコーポレイテッド 生体接着剤組成物及び活性薬剤の局所投与方法
US20060078604A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
JP2012503010A (ja) 2008-09-18 2012-02-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 小胞モノアミン輸送体２のベンゾキノリン阻害剤
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
JP2013528631A (ja) 2010-06-17 2013-07-11 エルテーエス ローマン テラピー−ジステーメ アーゲー メマンチンの経皮投与
JP2015515475A (ja) 2012-04-04 2015-05-28 イヴァックス・インターナショナル・ゲーエムベーハー 併用療法のための医薬組成物
JP2016520638A (ja) 2013-06-04 2016-07-14 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システム
JP2017514850A (ja) 2014-05-06 2017-06-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 多動性運動障害を処置するためのｖｍａｔ２インヒビター
WO2017003935A1 (en) 2015-06-27 2017-01-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system

Also Published As

Publication number Publication date
KR102952482B1 (ko) 2026-04-13
ES2968827T3 (es) 2024-05-14
ZA202006415B (en) 2024-04-24
TW202014187A (zh) 2020-04-16
BR112020021700A2 (pt) 2021-01-26
KR20210005623A (ko) 2021-01-14
IL278185A (https=) 2020-12-31
EP3784237A1 (en) 2021-03-03
EP3784237A4 (en) 2022-02-16
TWI832854B (zh) 2024-02-21
IL278185B2 (en) 2024-11-01
WO2019209940A1 (en) 2019-10-31
AU2019261403A1 (en) 2020-11-12
MX2020011269A (es) 2020-12-11
US20250144045A1 (en) 2025-05-08
CN112165942A (zh) 2021-01-01
US20210128490A1 (en) 2021-05-06
DK3784237T3 (da) 2024-01-08
CA3097189A1 (en) 2019-10-31
AU2019261403B2 (en) 2025-05-15
CN112165942B (zh) 2024-04-12
US12144899B2 (en) 2024-11-19
JP2021522240A (ja) 2021-08-30
IL278185B1 (en) 2024-07-01
EP3784237B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20250144045A1 (en) Tetrabenazine transdermal delivery device
KR101737960B1 (ko) 외용 의약 조성물
JP5354763B2 (ja) フェンタニルを投与するための経皮的張り付け剤
TW201521796A (zh) 用於經皮傳遞三級胺藥物之組合物及方法
EP1909773B1 (en) Transdermal system for varenicline
JP7709432B2 (ja) テトラベナジン経皮送達デバイス
WO2014199455A1 (ja) メマンチン経皮吸収型貼付製剤
RU2800536C2 (ru) Устройство для трансдермальной доставки тетрабеназина
RU2838380C1 (ru) Устройство для трансдермальной доставки тетрабеназина
HK40042329A (en) Tetrabenazine transdermal delivery device
HK40042329B (zh) 丁苯那嗪透皮输送装置
JP3193161B2 (ja) 経皮吸収性製剤
KR20200006065A (ko) 루파타딘-함유 패치
WO2018104772A1 (ja) 経皮吸収型製剤
HK40081373A (en) Tetrabenazine transdermal delivery device
JP2022532635A (ja) 高含量のドネペジル又はその塩を含む経皮吸収製剤
US20200375915A1 (en) Matrix adhesive patch and process for the preparation thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7386544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150